Showing 1071-1080 of 8921 results for "".
Selling Skin Care in Your Practice
https://practicaldermatology.com/topics/practice-management/selling-skin-care-in-your-practice/19294/While selling skin care products in your practice may seem like it has some disadvantages, Joel Schlessinger MD believes it's worth the extra work. During this video, Joel Schlessinger MD explains why he decided to sell products in his practice. Overall, he finds that selling items he recommends toFillers and Cosmetic Procedures
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/fillers-and-cosmetic-procedures/19367/Hayes B. Gladstone, MD discusses emerging options in the field of cosmetic dermatology, including new devices and injectables.Botox Cosmetic Patient Perceptions
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/botox-cosmetic-patient-perceptions/19382/Results of a survey by Allergan and Healthy Women reveal changing perceptions about treatment with the neurotoxin. Featuring Courtney Thorne-Smith.Dr. Chan Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-chan-discusses-experience-with-gemini-laser/19471/“Gemini is an extremely effective non-ablative skin rejuvenation laser. And by combining the 532 KTP lasers with the long pulse 1064 YAG, we can achieve non-ablative skin rejuvenations in terms of reductions of pigmentations, fine lines, pore size and vessel improvement.” & #8212Professor HenryDermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validaEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48959/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://practicaldermatology.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.Dermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sSpecial Considerations for Biologic Therapies in Pediatric and Adult Patients with Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37173/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, lists some of the most important considerations when prescribing biologic therapies for atopic dermatitis patients of